Convert Pharmaceuticals
Liège
About Convert Pharmaceuticals
Convert Pharmaceuticals is a clinical phase I-IIa drug development company, that is building a proprietary drug pipeline exploiting tumor microenvironment specific factors for therapeutic benefit. Convert’s lead product is a hypoxia activated prodrug (HAP). Hypoxia constitutes a therapeutic obstacle as it promotes the development of resistance to conventional anti-cancer treatments. Convert Pharmaceuticals combines proprietary insights in the tumor microenvironment with expertise in drug and biomarker development to develop effective and well-tolerated HAPs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $16.6M
- Funding stage: Seed
- Last round: Grant (Feb 2018)
- Website: convertpharma.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Business Development, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/convert-pharmaceuticals-10677 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.